

23 January 2026

Please vote for us <https://www.extelinsights.com/>**HBM Healthcare Investments**


Switzerland

Other Financials

Reuters: HBMN.S Bloomberg: HBMN SE

Add

Closing price as of 22-Jan-26	CHF 241.50
Target price	CHF 236.00
High/Low (12M)	CHF 241.50/159.60
Market cap.	CHF mn 1,626
Enterprise value	CHF mn 1,605
Free float	82.9%
Avg. daily turnover	CHF mn 1.42

Price relative to Index

Performance (%)	1M	3M	6M
Absolute	7.3	21.6	50.0
rel. SPI	6.1	16.0	39.8
rel. STOXX Europe 600	3.6	15.2	38.1
rel. SXXP Financial Serv.	3.8	13.7	44.6

Solid 9M delivery on broad-based portfolio strength**Our conclusion**

- **As expected, HBM delivered a very strong 9M25/26 performance**, benefiting from the broad-based recovery in global biotech markets and solid contributions from both public and private holdings. The +18% NAV increase, achieved despite material currency headwinds, underlines the quality of portfolio construction and the leverage to improving sector sentiment.
- **This furthers our positive outlook on HBM as a differentiated way to gain exposure to high-growth private biopharma assets** while steadily building a robust, long-term value creation track record. Successful monetization events, selective new investments on both private and public sides, comprising a deep pipeline of upcoming clinical and regulatory catalysts, continue to support the investment case.

Facts & Analysis

- **9M25/26 net profit reached CHF 286mn** (3Q25/26: CHF 191mn), despite negative FX effects of approx. CHF 180mn. NAV/Share increased by +18% to CHF 280.9, while the share price rose +29.3%, with the NAV discount reducing to approx. 19%.
- **Public assets generated CHF 233mn** of value over 9M (despite CHF 116mn negative FX), driven by strong performance in names such as Terns Pharmaceuticals, Zymeworks, Abivax, Merus, Travere Therapeutics and Upstream Bio, supported by positive clinical data and regulatory momentum.
- **Private investments contributed a net CHF 84mn**, with key value drivers from the majority sale of Swixx BioPharma (retained minority exposure), the Bluejay Therapeutics acquisition by Mirum, and continued valuation uplifts across core private holdings.
- **Asset mix remains balanced** (32% private, 51% public, of which 21% public from private), underscoring the disciplined investment philosophy. New investments in Synthon and Electra Therapeutics and follow-on capital into high-conviction names position the portfolio for continued NAV compounding.

Analyst:**Thomas Meyer**

+41 43 388 9265

tmeyer@helvea.com

Key financials

CHF mn	2024/25	2025/26E	2026/27E	2027/28E	CAGR (%)
Sales	41.9	35.1	134.4	141.6	50.1
EBIT adj.	15.8	10.2	109.5	116.7	94.9
EPS adj. (CHF)	2.74	1.22	15.97	17.04	83.9

Source: Company data, Baader Helvea Equity Research

Valuation ratios

x	2024/25	2025/26E	2026/27E	2027/28E
EV/Sales	31.2	46.3	11.9	10.6
EV/EBIT adj.	82.8	159.2	14.7	12.9
P/E adj.	69.1	198.0	15.1	14.2

HBM Healthcare Investments

Key data

FY 31 Mär.	2022/23	2023/24	2024/25	2025/26E	2026/27E	2027/28E
Share data						
EPS rep. (CHF)	-20.98	-0.16	2.74	1.22	15.97	17.04
EPS adj. (CHF)	-20.98	-0.16	2.74	1.22	15.97	17.04
Dividend (CHF)	9.70	7.52	7.53	7.76	7.38	7.38
Book value (CHF)	255.02	248.10	244.41	240.18	248.78	258.44
Free cash flow (CHF)	12.87	13.51	-8.83	9.67	10.42	23.04
Avg. no. of shares (mn)	6.9	6.9	6.7	6.7	6.7	6.7
Market cap. (avg./current, CHF mn)	1,595.3	1,267.1	1,273.8	1,625.8	1,625.8	1,625.8
Enterprise value (CHF mn)	1,512.4	1,163.0	1,307.1	1,623.9	1,605.4	1,502.0
Valuation						
P/E adj. (x)	-	-	69.1	198.0	15.1	14.2
P/BV (x)	0.9	0.7	0.8	1.0	1.0	0.9
FCF/EV (%)	5.9	8.0	-4.5	4.0	4.4	10.3
FCF yield (%), (FCF/Mcap.)	5.6	7.3	-4.7	4.0	4.3	9.5
Dividend yield (%)	4.2	4.1	4.0	3.2	3.1	3.1
EV/Sales (x)	-13.0	48.9	31.2	46.3	11.9	10.6
EV/EBITDA adj. (x)	-10.4	-451.8	82.8	159.2	14.7	12.9
EV/EBIT adj. (x)	-10.4	-451.8	82.8	159.2	14.7	12.9
EV/CE (x)	0.9	0.7	0.8	1.0	1.0	0.9
ROCE/WACC adj. (x)	-	-	-	-	-	-
Key company data						
Sales growth (%)	210.8	-120.4	76.1	-16.3	283.1	5.4
EBITDA growth adj. (%)	94.1	-98.2	-713.0	-35.4	973.7	6.6
EBITDA margin adj. (%)	125.4	-10.8	37.7	29.1	81.5	82.4
EBIT margin adj. (%)	125.4	-10.8	37.7	29.1	81.5	82.4
Net margin adj. (%)	124.7	-2.0	37.7	29.1	81.5	82.4
Free cash flow margin (%)	-76.5	390.3	-141.8	185.6	52.2	109.5
Payout ratio (%)	-46.3	-	321.3	512.0	45.3	42.5
Gearing (%), (net debt/equity)	-4.7	-6.1	2.0	-0.1	-1.2	-7.1
Net debt/EBITDA (x)	0.6	40.4	2.1	-0.2	-0.2	-1.1
Equity ratio (x), (equity/total assets)	90.7	93.4	92.8	92.7	92.9	98.4
Capital employed (CHF mn)	1,693.1	1,578.2	1,662.2	1,607.3	1,646.7	1,608.3
ROCE adj. (%)	-8.6	-0.2	0.9	0.6	6.7	7.3
Income statement (CHF mn)						
Turnover	-116.5	23.8	41.9	35.1	134.4	141.6
EBITDA	-146.1	-2.6	15.8	10.2	109.5	116.7
EBITDA adj.	-146.1	-2.6	15.8	10.2	109.5	116.7
EBIT	-146.1	-2.6	15.8	10.2	109.5	116.7
EBIT adj.	-146.1	-2.6	15.8	10.2	109.5	116.7
EBT	-145.3	-0.5	15.8	10.2	109.5	116.7
Net profit after minorities	-145.3	-0.5	15.8	10.2	109.5	116.7
Net profit adj.	-145.3	-0.5	15.8	10.2	109.5	116.7
Balance sheet (CHF mn)						
Non-current assets	1,714	1,607	1,693	1,607	1,647	1,608
thereof goodwill	-	-	-	-	-	-
Current assets	232	205	70	101	120	124
Total assets	1,946	1,813	1,764	1,744	1,802	1,768
Shareholders' equity	1,765	1,693	1,637	1,617	1,675	1,740
Total equity and liabilities	1,946	1,813	1,764	1,744	1,802	1,768
Net debt	-83	-104	33	-2	-20	-124
Cash flow (CHF mn)						
Cash flow from operations	-29.5	-25.6	-26.0	-24.9	-24.9	-24.9
of which change in working capital	0.0	0.0	0.0	0.0	0.0	0.0
Cash flow from investments	118.7	118.5	-33.4	90.0	95.0	180.0
of which investment in fixed assets	-	-	-	-	-	-
Free cash flow	89.1	92.9	-59.4	65.1	70.1	155.1
Dividends paid	-67.2	-51.7	-50.7	-52.2	-49.7	-49.7
Cash flow from financing activities	-74.3	-122.3	0.0	0.0	0.0	0.0
Change in cash position	8.4	-28.6	-137.2	0.0	0.0	0.0

Source: Company data, Baader Helvea Equity Research

HBM Healthcare Investments**Disclaimer****Baader Bank AG, Weihenstephaner Strasse 4, 85716 Unterschleissheim, Germany****Baader Helvea AG, Freigutstrasse 12, 8002 Zurich, Switzerland****Baader Helvea Limited, 5 Royal Exchange Buildings, London EC3V 3NL, United Kingdom**

Baader Bank AG is the parent company of Baader Helvea AG and/or Baader Helvea Limited. Baader Bank AG, Baader Helvea AG and Baader Helvea Limited are collectively referred to as "**Baader Helvea Group Europe Companies**" below, and each of them is referred to separately as a "**Baader Helvea Group Europe Company**". Baader Bank AG and its subsidiaries and affiliates, including Baader Helvea AG and Baader Helvea Limited, are collectively referred to below as the "**Group Companies**".

The information set forth in this document has been diligently compiled by Baader Bank AG and is partially based on publicly available sources and data supplied by third parties (including data supplied by AlphaValue S.A., a cooperation partner of Baader Bank AG) believed to be reliable. Baader Bank AG does not warrant the accuracy or completeness of such information.

All estimates and opinions included herein represent the independent judgment of the analyst(s) named in the Research Document as of the date of publication of this Research Document.

This Research Document was completed at 08:20 AM (CET) on 23-01-2026.

The relevant Baader Helvea Group Europe Company reserves the right to modify the views expressed herein at any time without notice and the right not to update this information and to discontinue coverage of the company that is the subject of this Research Document without notice. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. Neither the Group Companies, any of their authorized representatives or employees nor any other person accepts any liability whatsoever for any loss arising from any use of this Research Document or its contents or otherwise arising in connection therewith.

Please note the information on the preparation of this document, the important notice, the advice regarding possible conflicts of interests, and the mandatory information required by Art. 20 of the Regulation (EU) No 596/2014 of 16 April 2014 and the Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 and pursuant to Art. 34, 36 and 37 of the Commission Delegated Regulation (EU) No 2017/565 of 25 April 2016 and other applicable rules under https://www.baaderbank.de/disclaimer_Research.

Baader Bank AG is a stock corporation (*Aktiengesellschaft*) organized under the laws of the Federal Republic of Germany with its principal place of business in Unterschleissheim. It is registered with the District Court (*Amtsgericht*) in Munich under No. HRB 121537 and supervised by the German Financial Supervisory Authority (*Bundesanstalt für Finanzdienstleistungsaufsicht – BaFin*), Marie-Curie-Strasse 24-28, 60439 Frankfurt am Main and Graurheindorfer Strasse 108, 53117 Bonn. The value added tax identification number of Baader Bank AG is DE 114123893.

A list of all of our Research Documents on any financial instrument or issuer that were disseminated during the preceding 12-month period is available to our clients under https://www.baaderbank.de/disclaimer_Research.

Research Documents with recommendation changes (rating or target price) published in the twelve months prior to the publication of this Research Document covering the same financial instruments or issuers.

Company	Date	Rating	Currency	Target price	Closing price as of	Analyst
---------	------	--------	----------	--------------	---------------------	---------

HBM Healthcare Investments**Contacts****Markus Mayer**

Head of Capital Markets
+49 89 5150 1818
markus.mayer@baaderbank.de

Volker Bosse, CEFA

Head of Research
+49 89 5150 1815
volker.bosse@baaderbank.de

FOR MORE DETAILS ON OUR BAADER EUROPE COVERAGE PLEASE VISIT OUR RESEARCH PLATFORM**CORPORATE ACCESS**

Kerstin Kugler +49 89 5150 1891
Paula Reinhardt +49 160 92330618
kerstin.kugler@baaderbank.de
paula.reinhardt@baaderbank.de

EQUITY RESEARCH

Volker Bosse, CEFA +49 89 5150 1815
Head of Research
volker.bosse@baaderbank.de

For an overview of the responsible analysts please visit our Baader Europe webpage

EQUITY STRATEGY

Gerhard Schwarz, CEFA +49 89 5150 1812
Head of Equity Strategy
gerhard.schwarz@baaderbank.de

RESEARCH PRODUCTION

Rene Rückert +49 89 5150 1896
Head of Research Production
rene.rueckert@baaderbank.de

Maria Koletzko +49 89 5150 1889
Kerstin Kugler +49 89 5150 1891
maria.koletzko@baaderbank.de
kerstin.kugler@baaderbank.de

EQUITY SALES

Frankfurt +49 69 1388 1357
London +44 20 7054 7100
Munich +49 89 5150 1850
Zurich +41 43 388 9200

DERIVATIVES SALES

Munich +49 89 5150 1990

EQUITY SALES TRADING

Frankfurt +49 69 1388 1355
London +44 20 7054 7100
Munich +49 89 5150 1870
New York +1 212 935 5150
Zurich +41 43 388 9200

For North American clients:
New York +1 212 935 5150

PUBLICATION ADDRESSES

Baader Bank AG
Equity Research
Weihenstephaner Strasse 4
85716 Unterschleissheim, Germany

T +49 89 5150 1810

Baader Helvea AG
Equity Research
Freigutstrasse 12
8002 Zurich, Switzerland

T +41 43 388 9250